|
|
||||||||
From the Department of Neurology (Drs. Gilman, Chervin, Consens, and Junck, M. Heumann); Division of Nuclear Medicine (Dr. Koeppe), Department of Radiology; and Department of Biostatistics(Dr. Little, H. An); University of Michigan, Ann Arbor.
Address correspondence and reprint requests to Dr. S. Gilman, Department of Neurology, University of Michigan Health System, 1500 E. Medical Center Dr., Ann Arbor, MI 48109-0316; e-mail: sgilman{at}umich.edu
Objective: To explore the neurochemical basis of obstructive sleep apnea (OSA) in multiple-system atrophy (MSA).
Methods: In 13 patients with probable MSA, nocturnal, laboratory-based polysomnography was used to rate the severity of OSA using the apneahypopnea index during sleep. SPECT with (-)-5-[123I]iodobenzovesamicol ([123I]IBVM) was utilized to measure the density of thalamic cholinergic terminals, which project from the brainstem pedunculopontine and laterodorsal tegmental nuclei. PET with (+)-[11C]dihydrotetrabenazine ([11C]DTBZ) was also used to measure the density of striatal monoaminergic terminals, which project from the brainstem. Findings in the patient group were compared with data from 12 normal control subjects scanned utilizing [123I]IBVM and 15 normal control subjects utilizing [11C]DTBZ.
Results: Age and gender distributions were similar in patient and control groups. The MSA subjects showed decreased [123I]IBVM binding in the thalamus (p < 0.001) and decreased mean [11C]DTBZ binding in the striatum (p < 0.0001) in comparison with the control subjects. In the MSA group, thalamic [123I]IBVM binding was inversely correlated with the severity of OSA (p = 0.011). Striatal [11C]DTBZ binding was not correlated with the severity of OSA (p = 0.19).
Conclusion: Decreased pontine cholinergic projections may contribute to OSA in MSA.
This article has been cited by other articles:
![]() |
G. Jayaraman, H. Sharafkhaneh, M. Hirshkowitz, and A. Sharafkhaneh Review: Pharmacotherapy of obstructive sleep apnea Therapeutic Advances in Respiratory Disease, December 1, 2008; 2(6): 375 - 386. [Abstract] [PDF] |
||||
![]() |
W. Moraes, D. Poyares, L. Sukys-Claudino, C. Guilleminault, and S. Tufik Donepezil Improves Obstructive Sleep Apnea in Alzheimer Disease: A Double-Blind, Placebo-Controlled Study Chest, March 1, 2008; 133(3): 677 - 683. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Douglas, G. N. Bowman, H. A. Baghdoyan, and R. Lydic C57BL/6J and B6.V-LEPOB mice differ in the cholinergic modulation of sleep and breathing J Appl Physiol, March 1, 2005; 98(3): 918 - 929. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Gottlieb, A. L. DeStefano, D. J. Foley, E. Mignot, S. Redline, R. J. Givelber, and T. Young APOE {epsilon}4 is associated with obstructive sleep apnea/hypopnea: The Sleep Heart Health Study Neurology, August 24, 2004; 63(4): 664 - 668. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Hedner, H. Kraiczi, Y. Peker, and P. Murphy Reduction of Sleep-disordered Breathing after Physostigmine Am. J. Respir. Crit. Care Med., November 15, 2003; 168(10): 1246 - 1251. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |